Loading...
•
Sep 30, 2020
Enliven Therapeutics Q3 2020 Earnings Report
Reported financial results for the third quarter ended September 30, 2020 and reviewed recent business highlights.
Key Takeaways
Imara Inc. reported its third quarter 2020 financial results, highlighting the ongoing Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia, as well as the Orphan Drug designation granted by the European Commission for sickle cell disease.
Patient dosing is underway in Phase 2b clinical trials of IMR-687 for sickle cell disease and beta-thalassemia.
The European Commission granted IMR-687 Orphan Drug designation for sickle cell disease.
Dosing was completed in the Phase 2a clinical trial in patients with Sickle Cell Disease during the third quarter of 2020.
Cash, cash equivalents and investments were $96.1 million as of September 30, 2020.
Forward Guidance
Imara Inc. provided financial guidance for the full year 2020 and expects that its cash, cash equivalents and investments as of September 30, 2020, will be sufficient to enable it to fund its planned operations into mid-2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...